Lupin Share Price
As on 17 December 2025 at 15:04 IST
Lupin Q1 FY26 Results:
Net profit rose 52% to ₹1,219 crores, compared to ₹801 crores in Q1 FY25. Total income in Q1 FY26 increased 12% to ₹6,347 crores from ₹5,668 crores in the same period last year.
About Lupin Ltd
Lupin Limited is a leading Indian multinational pharmaceutical company. It has established itself as a major player in the global healthcare industry. The company was founded by Desh Bandhu Gupta in 1968. It has grown into one of the largest generic pharmaceutical companies worldwide by revenue with decades of experience since its inception. The headquarters of the company is located in Mumbai, Maharashtra, India. Primary products of Lupin Limited include generic drugs, biosimilars, and specialty medicines. The company’s focus spans key therapeutic areas such as pediatrics and anti-tuberculosis treatments. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
1.88%
Over 6 Months
3.96%
Over 1 Year
1.32%
Over 3 Years
186.66%
Lupin Ltd Summary
Close ₹2,090.60
Open ₹2,096.60
High ₹2,099.90
Low ₹2,077.60
Volume 6,04,167
Net Turnover (in Cr) ₹126.27
52Wk High ₹2,402.90
52Wk Low ₹1,795.20
52Wk High / Low
1,795.20
2,402.90
Lupin Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹95,498.36
EPS (TTM) 116.80
Book Value (BV) 595.99
Div. Yield 0.57 %
P/E (TTM) 16.57
Price/Book Value 3.51
Delivery % 73.60 %
Face Value 2
Key Ratios
PE Ratio 23.29
PB Ratio 3.81
EV to Sales 5.44
PEG Ratio 0.33
ROA 15.87
ROE 17.70
Debt-Equity 0.01
Net Profit Margin 23.42
Operating Profit Margin 32.82
Lupin Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 22,909.51 | 20,141.50 | 16,792.57 | 16,615.57 | 15,299.25 |
| Total Expenses | 18,894.51 | 17,719.23 | 16,076.08 | 17,988.14 | 13,624.13 |
| Profit Before Tax | 4,015 | 2,422.27 | 716.49 | -1,372.21 | 1,676.45 |
| Profit After Tax | 3,306.26 | 1,935.57 | 447.69 | -1,509.36 | 1,227.93 |
| Operating Profit After Depreciation | 4,309.87 | 2,733.88 | 990.79 | -1,229.80 | 1,815.76 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 9,880.54 | 9,055.16 | 8,698.41 | 7,680.43 | 8,095.48 |
| Total Non Current Assets | 12,406.30 | 10,549.53 | 10,504.63 | 9,363.54 | 9,624.07 |
| Total Current Assets | 16,798.58 | 13,447.65 | 12,451.30 | 12,457.68 | 13,986.37 |
| Total Assets | 29,204.88 | 23,997.18 | 22,955.93 | 21,821.22 | 23,610.44 |
| Total Shareholder's Fund | 17,203.50 | 14,290.29 | 12,464.50 | 12,153.27 | 13,803.14 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 2,999.94 | 3,648.36 | 1,897.24 | 367.31 | 1,821.76 |
| Net Cash Used In Investing Activities | -4,171.89 | -1,712.20 | -1,286.77 | 1,292.23 | -1,239.58 |
| Net Cash Used In Financing Activities | 1,731.88 | -2,184.21 | -337.25 | -1,572.32 | -1,885.27 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 17,220.89 | 14,782.01 | 11,468.85 | 11,988.66 | 11,185.02 |
| Total Expenses | 12,306.55 | 11,997.32 | 10,941.71 | 12,150.19 | 9,555.32 |
| Profit Before Tax | 4,837.12 | 2,784.69 | 527.14 | -161.53 | 1,629.70 |
| Profit After Tax | 3,972.96 | 2,326.09 | 425.21 | -188.70 | 1,258.62 |
| Operating Profit After Depreciation | 4,998.84 | 2,841.04 | 625.58 | -88.06 | 1,670.32 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 4,992.33 | 4,147.88 | 4,210.53 | 3,863.88 | 3,793.86 |
| Total Non Current Assets | 16,537.44 | 15,634.99 | 15,112.75 | 13,875.55 | 12,241.19 |
| Total Current Assets | 11,894.55 | 9,287.87 | 7,570.92 | 8,437.82 | 9,617.37 |
| Total Assets | 28,431.99 | 24,922.86 | 22,683.67 | 22,313.37 | 21,858.56 |
| Total Shareholder's Fund | 24,278.24 | 20,603.09 | 18,411.86 | 18,150.19 | 18,565.57 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 2,444.65 | 2,504.13 | 1,793.99 | 151.03 | 1,570.08 |
| Net Cash Used In Investing Activities | -1,766.32 | -1,599.02 | -1,269.17 | -371.79 | -2,507.52 |
| Net Cash Used In Financing Activities | -460.23 | -867.07 | -498.26 | 102.45 | -53.17 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 7,047.51 | 6,268.34 | 5,667.13 | 5,767.71 | 5,672.73 |
| Total Expenses | 4,706.18 | 4,541.10 | 4,345.96 | 4,411.81 | 4,332.37 |
| Profit Before Tax | 2,006.97 | 1,415.54 | 895.84 | 1,071.27 | 1,054.86 |
| Profit After Tax | 1,484.83 | 1,221.46 | 782.38 | 858.86 | 859.48 |
| Operating Profit after Depreciation | 2,431.33 | 1,806.28 | 1,378.12 | 1,409.61 | 1,382.65 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 4,068.28 | 5,708.59 | 4,485.67 | 4,208 | 4,106.20 |
| Total Expenses | 2,892.65 | 2,978.95 | 2,739.54 | 2,796.95 | 2,991.45 |
| Profit Before Tax | 1,635.81 | 2,588.15 | 1,553.09 | 1,217.06 | 984.05 |
| Profit After Tax | 1,357.35 | 2,128.07 | 1,291.35 | 984.67 | 807.76 |
| Operating Profit after Depreciation | 1,245.63 | 2,783.78 | 1,794.92 | 1,466.35 | 1,147.37 |
Lupin Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 2,078.83
S2 2,067.07
S3 2,056.53
Pivot 2,089.37
R1 2,101.13
R2 2,111.67
R3 2,123.43
Moving Average
20 SMA 2,067.25
50 SMA 2,007.01
100 SMA 1,981.47
200 SMA 1,985.67
Lupin Ltd Corporate Actions
Lupin Ltd
₹12.0/Share
Announcement Date 25 Jul 2025
Record Date 25 Jul 2025
Div Yield 600%
Lupin Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,782.80 | ₹4,27,753.44 |
| Divis Laboratories Ltd | ₹6,336.15 | ₹1,68,204.87 |
| Torrent Pharmaceuticals Ltd | ₹3,757.45 | ₹1,27,163.47 |
| Cipla Ltd | ₹1,500 | ₹1,21,165.68 |
| Dr Reddys Laboratories Ltd | ₹1,279 | ₹1,06,749.22 |
Lupin Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Nippon India Pharma Fund | 7.59% |
| Mirae Asset Midcap Fund | 3.21% |
| HDFC Large Cap Fund | 2.37% |
| Mirae Asset Large & Midcap Fund | 2.05% |
| SBI ELSS Tax Saver Fund | 1.73% |
Lupin Ltd News
Lupin receives SBTi validation for its climate targets
16 Dec 2025, 10:06 am
Lupin Manufacturing Solutions partners with PolyPeptide Group AG
To support rapidly expanding global peptides market
12 Dec 2025, 12:14 pm
Lupin receives USFDA tentative approval for Siponimod Tablets
05 Dec 2025, 11:15 am
Lupin receives USFDA tentative nod for Siponimod tablets
Lupin announced that it has received tentative approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Siponimod Tablets in 0.25 mg, 1 mg and 2 mg.
05 Dec 2025, 10:05 am
Lupin enters into exclusive licensing agreement with Valorum Biologics
For commercialization and distribution of Armlupeg' in US market
04 Dec 2025, 03:50 pm
Lupin Ltd Stock Analysis
- Annual revenue for Lupin Ltd increased by 16.50% to ₹17,220.89 crore in FY 2025 from ₹14,782.01 crore in FY 2024.
- Annual Net Profit for Lupin Ltd increased by 70.80% to ₹3,972.96 crore in FY 2025 from ₹2,326.09 crore in FY 2024.
- Promoter Shareholding in Lupin Ltd decreased by 0.01% in the most recent quarter, from 46.90% in June 2025 to 46.90% in September 2025.
- Lupin Ltd delivered a 1-year return of 1.32% compared to the Nifty 50, which provided a return of 4.83% as of the last trading session.
- Lupin Ltd share price moved up by 1.54% from its previous close of INR ₹2,090.60. The latest Lupin Ltd share price is INR ₹2,122.80.
- Lupin Ltd share price today has been at a low of 2,095.90 and a high of 2,128. Over the past 52 weeks, the Lupin Ltd share price has seen a low of 1,795.20 and a high of 2,402.90.
About Lupin Ltd
Lupin Limited is a leading Indian multinational pharmaceutical company. It has established itself as a major player in the global healthcare industry since its inception in 1968. With decades of experience, Lupin has grown into one of the largest generic pharmaceutical companies worldwide by revenue.
Headquartered in Mumbai, Maharashtra, Lupin specialises in developing and distributing various healthcare products. Its portfolio includes generic drugs, active pharmaceutical ingredients (APIs), biosimilars, and specialty medicines. The company’s focus spans key therapeutic areas such as paediatrics and anti-tuberculosis treatments.
Founded by Desh Bandhu Gupta, Lupin remains a family-driven enterprise. Vinita D. Gupta serves as CEO, and Nilesh Gupta is the Managing Director. This leadership structure guides Lupin's strategic direction and operations. Lupin’s influence extends far beyond India, with a strong presence in over 100 countries. Key markets include the United States, Europe, Japan, and India. This underscores the company's global reach and impact in the pharmaceutical sector.
Operating from its registered office at Kalpataru Inspire, Mumbai, Lupin continues to expand its market share and product offerings. The registrar’s office is L.B.S. Marg, Vikhroli. It is not currently the top-ranked stock in its sector. However, the company's global revenue cements its position as a major pharmaceutical player.
The Gupta family maintains primary promoter shareholding, providing stability to the company's operations. This family backing positions Lupin as a crucial institution in the pharmaceutical industry. As Lupin navigates the evolving healthcare landscape, it is committed to innovation and global expansion. As a result, it is building on its rich legacy in pharmaceutical development and distribution.
Lupin’s manufacturing prowess is built on a foundation of advanced technology. The company operates 15 cGMP-compliant manufacturing facilities across three continents. These facilities are equipped with cutting-edge technology. They also adhere to the highest national and international standards. This ensures the quality, safety, and efficacy of Lupin’s products. The company’s ability to scale its operations is also a testament to its robust infrastructure and strategic investments.
One of the key aspects of Lupin’s manufacturing excellence is its focus on operational efficiency. The company has adopted advanced manufacturing processes, such as continuous flow reactors. These technologies allow for precise control over production parameters. This leads to consistent product quality and significant cost savings. Lupin can accelerate product development by streamlining production processes. This ensures that patients have timely access to essential medications.
Lupin’s commitment to quality is further reinforced by its stringent quality control measures. The company adheres to global quality standards, including cGMP and cGLP norms. Regular inspections and audits by regulatory authorities such as the US FDA, WHO, TGA (Australia), MHLW (Japan) and MCC (South Africa) ensure that Lupin’s manufacturing facilities maintain the highest standards of quality and compliance. This approach to quality control ensures that every product meets the highest standards of purity and safety.
In addition to its focus on quality and efficiency, Lupin places a strong emphasis on sustainability. The company has implemented various measures to reduce its environmental impact. For instance, Lupin’s continuous flow reactors enhance efficiency and reduce the carbon footprint. So, by adopting green chemistry principles and optimising resource utilisation, Lupin ensures that its manufacturing operations are environmentally responsible.
Lupin’s manufacturing excellence is also driven by its commitment to innovation. The company invests heavily in research and development. This is to stay at the forefront of pharmaceutical manufacturing technology. Lupin’s R&D efforts focus on developing new formulations and exploring novel manufacturing techniques. This commitment to innovation enables Lupin to continuously enhance its manufacturing capabilities. It also helps them deliver high-quality products to patients worldwide.
The company’s global supply chain is another critical component of its manufacturing excellence. Lupin’s supply chain operations are aligned with global commercial plans and protocols. This ensures the smooth transfer of inputs into its plants and the timely output of products to consumers worldwide. The company’s ability to maintain high levels of on-time delivery is also a testament to its efficient supply chain management. This ensures the company meets customer needs consistently and competitively.
Lupin’s manufacturing excellence is also reflected in its partnerships and collaborations. The company works closely with contract manufacturing organisations to expand production capacities. These partnerships enable the company to leverage external expertise and resources, further strengthening its manufacturing capabilities. As a result, Lupin stays ahead of industry trends.
Lupin Limited’s manufacturing excellence is due to its commitment to quality and innovation. The company’s quality control measures and advanced manufacturing technologies ensure that it delivers quality pharmaceutical products. Lupin’s focus on continuous improvement and strategic partnerships further enhances its manufacturing capabilities. This has positioned it as a leader in the global pharmaceutical industry.
Headquartered in Mumbai, Maharashtra, Lupin specialises in developing and distributing various healthcare products. Its portfolio includes generic drugs, active pharmaceutical ingredients (APIs), biosimilars, and specialty medicines. The company’s focus spans key therapeutic areas such as paediatrics and anti-tuberculosis treatments.
Founded by Desh Bandhu Gupta, Lupin remains a family-driven enterprise. Vinita D. Gupta serves as CEO, and Nilesh Gupta is the Managing Director. This leadership structure guides Lupin's strategic direction and operations. Lupin’s influence extends far beyond India, with a strong presence in over 100 countries. Key markets include the United States, Europe, Japan, and India. This underscores the company's global reach and impact in the pharmaceutical sector.
Operating from its registered office at Kalpataru Inspire, Mumbai, Lupin continues to expand its market share and product offerings. The registrar’s office is L.B.S. Marg, Vikhroli. It is not currently the top-ranked stock in its sector. However, the company's global revenue cements its position as a major pharmaceutical player.
The Gupta family maintains primary promoter shareholding, providing stability to the company's operations. This family backing positions Lupin as a crucial institution in the pharmaceutical industry. As Lupin navigates the evolving healthcare landscape, it is committed to innovation and global expansion. As a result, it is building on its rich legacy in pharmaceutical development and distribution.
Lupin’s Manufacturing Excellence - Quality at Scale
Lupin Limited has established itself as a benchmark for manufacturing excellence. The company’s commitment to quality and scale is evident in its manufacturing facilities and its rigorous adherence to global standards. This dedication ensures that Lupin consistently delivers high-quality pharmaceutical products to markets worldwide.Lupin’s manufacturing prowess is built on a foundation of advanced technology. The company operates 15 cGMP-compliant manufacturing facilities across three continents. These facilities are equipped with cutting-edge technology. They also adhere to the highest national and international standards. This ensures the quality, safety, and efficacy of Lupin’s products. The company’s ability to scale its operations is also a testament to its robust infrastructure and strategic investments.
One of the key aspects of Lupin’s manufacturing excellence is its focus on operational efficiency. The company has adopted advanced manufacturing processes, such as continuous flow reactors. These technologies allow for precise control over production parameters. This leads to consistent product quality and significant cost savings. Lupin can accelerate product development by streamlining production processes. This ensures that patients have timely access to essential medications.
Lupin’s commitment to quality is further reinforced by its stringent quality control measures. The company adheres to global quality standards, including cGMP and cGLP norms. Regular inspections and audits by regulatory authorities such as the US FDA, WHO, TGA (Australia), MHLW (Japan) and MCC (South Africa) ensure that Lupin’s manufacturing facilities maintain the highest standards of quality and compliance. This approach to quality control ensures that every product meets the highest standards of purity and safety.
In addition to its focus on quality and efficiency, Lupin places a strong emphasis on sustainability. The company has implemented various measures to reduce its environmental impact. For instance, Lupin’s continuous flow reactors enhance efficiency and reduce the carbon footprint. So, by adopting green chemistry principles and optimising resource utilisation, Lupin ensures that its manufacturing operations are environmentally responsible.
Lupin’s manufacturing excellence is also driven by its commitment to innovation. The company invests heavily in research and development. This is to stay at the forefront of pharmaceutical manufacturing technology. Lupin’s R&D efforts focus on developing new formulations and exploring novel manufacturing techniques. This commitment to innovation enables Lupin to continuously enhance its manufacturing capabilities. It also helps them deliver high-quality products to patients worldwide.
The company’s global supply chain is another critical component of its manufacturing excellence. Lupin’s supply chain operations are aligned with global commercial plans and protocols. This ensures the smooth transfer of inputs into its plants and the timely output of products to consumers worldwide. The company’s ability to maintain high levels of on-time delivery is also a testament to its efficient supply chain management. This ensures the company meets customer needs consistently and competitively.
Lupin’s manufacturing excellence is also reflected in its partnerships and collaborations. The company works closely with contract manufacturing organisations to expand production capacities. These partnerships enable the company to leverage external expertise and resources, further strengthening its manufacturing capabilities. As a result, Lupin stays ahead of industry trends.
Lupin Limited’s manufacturing excellence is due to its commitment to quality and innovation. The company’s quality control measures and advanced manufacturing technologies ensure that it delivers quality pharmaceutical products. Lupin’s focus on continuous improvement and strategic partnerships further enhances its manufacturing capabilities. This has positioned it as a leader in the global pharmaceutical industry.
FAQ’s
What is the share price of Lupin Ltd today?
Lupin Ltd share price as on 17 Dec 2025 is ₹ 2122.8
What is the Market Cap of Lupin Ltd?
The market cap of Lupin Ltd stock is ₹95,498.36 Cr.
What is the PE Ratio of Lupin Ltd?
The Price to Earnings (P/E) Ratio of Lupin Ltd is 23.29
What is the PB Ratio of Lupin Ltd?
The Price to Book (P/B) Ratio of Lupin Ltd is 3.81
What is the 52 week high of Lupin Ltd Share Price?
The 52 week high of Lupin Ltd share price stands at ₹2,402.90
What is the 52 week low of Lupin Ltd Share Price?
The 52 week low of Lupin Ltd share price stands at ₹1,795.20
How can I buy shares of Lupin Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Lupin Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
